Meta AnalysisID 1528
SeHCAT（牛磺硒胆酸[75硒]）用于调查胆汁酸吸收不良和测量胆汁酸池丢失的系统评价和经济学评价
CRD42012001911
To evaluate the clinical and cost effectiveness of [75Se] tauroselcholic acid (SeHCAT), a bile acid analogue which is used as a test for investigating bile acid malabsorption (BAM) and the measurement of bile acid pool l
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 1528
- Evidence Id
- 10086
- Core Evidence Id
- 10086
- Source Meta Analysis Id
- 1483
- Herb2 Meta Analysis Id
- HBMA001483
- Crd Id
- CRD42012001911
- Title
- A systematic review and economic evaluation of SeHCAT (Tauroselcholic [75Selenium] acid) for the investigation of bile acid malabsorption (BAM) and measurement of bile acid pool loss
- Review Question
- To evaluate the clinical and cost effectiveness of [75Se] tauroselcholic acid (SeHCAT), a bile acid analogue which is used as a test for investigating bile acid malabsorption (BAM) and the measurement of bile acid pool loss in patients referred to a GI clinic for investigation and diagnosis of BAM.
- Study Type Included
- The following types of studies will be included: • Randomised or non-randomised controlled trials, where participants are assigned to the intervention or comparator tests, for treatment planning, and outcomes are compared at follow-up. • Observational studies which report the results of multi-variable regression modelling with clinical outcome as the dependent variable and index test result as an independent variable. Included studies should control adequately for potential confounders (e.g. age, gender, disease, etc.). The following study/publication types will be excluded: • Pre-clinical and animal • Reviews, editorials, and opinion pieces • Case reports • Studies reporting only technical aspects of the test, or image quality • Studies with <10 participants
- Condition Being Studied
- Participant
- Animal
- Human Disease Modelled
- Intervention
- SeHCAT (GE Healthcare) is a radiopharmaceutical that is licensed for use in the investigation of bile acid malabsorption (BAM) and measurement of bile acid pool loss.
- Comparator Control
- The comparator will be no SeHCAT test (the current situation).
- Main Outcome
- Outcome Measure
- Additional Outcome
- Study Method
- Keyword
- Humans; Intestinal Absorption; Malabsorption Syndromes; Radiopharmaceuticals; Selenium Radioisotopes; Taurocholic Acid
- Contact
- Organisational Affiliation
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- England, Netherlands
- Review Stage
- First Submission Date
- Registration Date
- 2012-01-11
- Anticipated Start Date
- Anticipated Completion Date
- Title Cn
- SeHCAT（牛磺硒胆酸[75硒]）用于调查胆汁酸吸收不良和测量胆汁酸池丢失的系统评价和经济学评价
- Title En
- A systematic review and economic evaluation of SeHCAT (Tauroselcholic [75Selenium] acid) for the investigation of bile acid malabsorption (BAM) and measurement of bile acid pool loss
- Bilingual Status
- complete